The personalized advantage index: Translating research on prediction into individualized treatment recommendations. A demonstration

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  DeRubeis, Robert J ^a   Cohen, Zachary D ^a   Forand, Nicholas R ^b   Fournier, Jay C ^c   Gelfand, Lois A ^a   Lorenzo Luaces, Lorenzo ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE;

ANALYTICAL PARAMETERS; ARTICLE; CLINICAL RESEARCH; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED STUDY; EMPLOYMENT STATUS; HAMILTON SCALE; HUMAN; LIFE EVENT; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MARRIAGE; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; PERSONALITY DISORDER; PERSONALIZED ADVANTAGE INDEX; PERSONALIZED MEDICINE; PREDICTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; DEPRESSIVE DISORDER, MAJOR; HEALTH PLANNING GUIDELINES; HUMANS; INDIVIDUALIZED MEDICINE; PROGNOSIS; PSYCHIATRIC STATUS RATING SCALES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84896694905     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0083875     Document Type: Article

References (42)

1. Hamburg MA, Collins FS (2010) The Path to Personalized Medicine. New England Journal of Medicine 363: 301-304. doi:10.1056/NEJMp1006304.
2. Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, et al. (2010) Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 11: 1149-1167. doi:10.2217/pgs.10.97.
3. Schosser A, Kasper S (2009) The role of pharmacogenetics in the treatment of depression and anxiety disorders. International Clinical Psychopharmacology 24: 277-288. doi:10.1097/YIC.0b013e3283306a2f.
4. Simon GE, Perlis RH (2010) Personalized medicine for depression: can we match patients with treatments? Am J Psychiatry 167: 1445-1455. Available: http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id= 20843873&retmode=ref&cmd=prlinks.
5. McClay JL, Adkins DE, Åberg K, Stroup S, Perkins DO, et al. (2011) Genomewide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry 16: 76-85. doi:10.1038/mp.2009.89.
6. Malhotra AK, Zhang J-P, Lencz T (2012) Pharmacogenetics in psychiatry: translating research into clinical practice. Mol Psychiatry 17: 760-769. doi:10.1038/mp.2011.146.
7. Guo Y, DuBois Bowman F, Kilts C (2008) Predicting the brain response to treatment using a Bayesian hierarchical model with application to a study of schizophrenia. Hum Brain Mapp 29: 1092-1109. doi:10.1002/hbm.20450.
8. Gong Q, Wu Q, Scarpazza C, Lui S, Jia Z, et al. (2011) Prognostic prediction of therapeutic response in depression using high-field MR imaging. NeuroImage 55: 1497-1503. doi:10.1016/j.neuroimage.2010.11.079.
9. Baskaran A, Milev R, McIntyre RS (2012) The neurobiology of the EEG biomarker as a predictor of treatment response in depression. Neuropharmacology 63: 507-513. doi:10.1016/j.neuropharm.2012.04.021.
10. Leykin Y, Amsterdam JD, DeRubeis RJ, Gallop R, Shelton RC, et al. (2007) Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J Consult Clin Psychol 75: 267-276. doi:10.1037/0022-006X.75.2.267. (Pubitemid 47444731)
11. Fournier JC, DeRubeis RJ, Shelton RC, Gallop R, Amsterdam JD, et al. (2008) Anti-depressant medications v. cognitive therapy in people with depression with or without personality disorder. The British Journal of Psychiatry 192: 124-129. doi:10.1192/bjp.bp.107.037234. (Pubitemid 351269646)
12. Fournier JC, DeRubeis RJ, Shelton RC, Hollon SD, Amsterdam JD, et al. (2009) Prediction of response to medication and cognitive therapy in the treatment of moderate to severe depression. J Consult Clin Psychol 77: 775-787. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd= Retrieve&dopt=AbstractPlus&list-uids=19634969.
13. Jarrett RB, Schaffer M, McIntire D, Witt-Browder A, Kraft D, et al. (1999) Treatment of atypical depression with cognitive therapy or phenelzine: a doubleblind, placebo-controlled trial. Arch Gen Psychiatry 56: 431-437. doi:10.1001/archpsyc.56.5.431. (Pubitemid 29215432)
14. Dawes RM, Faust D, Meehl PE (1989) Clinical versus actuarial judgment. Science 243: 1668-1674.
15. Barber JP, Muenz LR (1996) The role of avoidance and obsessiveness in matching patients to cognitive and interpersonal psychotherapy: Empirical findings from the Treatment for Depression Collaborative Research Program. J Consult Clin Psychol 64: 951.
16. DeRubeis RJ, Hollon SD, Amsterdam JD, Shelton RC, Young PR, et al. (2005) Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 62: 409-416. doi:10.1001/archpsyc.62.4.409. (Pubitemid 40471690)
17. Hollon SD,DeRubeis RJ, SheltonRC, AmsterdamJD, Salomon RMR, et al. (2005) Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 62: 417-422. Available: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd= Retrieve&dopt=AbstractPlus&list-uids=15809409.
18. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62. doi:10.1016/j.jad.2012.02.042.
19. National Institute for Clinical Excellence (2004) Depression: Management of Depression in Primary and Secondary Care. London, England: National Institute for Clinical Excellence.
20. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, et al. (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5: e45-e45. doi:10.1371/journal. pmed.0050045.
21. Draper NR, Smith H (2003) Applied regression analysis. Singapore: John Wiley and Sons.
22. Hollon SD, Beck AT (1986) Predicting outcome versus differential response: Matching clients to treatment. Rockville, MD.
23. Zachary RA, Western Psychological Services Firm (1991) Shipley Institute of Living Scale. Los Angeles, CA: WPS, Western Psychological Services.
24. Kraemer H, Blasey C (2004) Centring in regression analyses: a strategy to prevent errors in statistical inference. International Journal of Methods in Psychiatric Research 13: 141-151. (Pubitemid 39264454)
25. Efron B, Gong G (1983) A leisurely look at the bootstrap, the jackknife, and cross-validation. The American Statistician 37: 36-48.
26. Harrell FE, Lee KL, Mark DB (1996) Tutorial in biostatistics multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387. Available: http://www.unt.edu/rss/class/Jon/MiscDocs/Harrell-1996.pdf.
27. Abdi H, Williams LJ (2010) Jackknife. In Salkind NJ, Dougherty DM, Frey B, editors. Encyclopedia of Research Design. Thousand Oaks, CA: Sage Publications, Incorporated. pp. 655-60.
28. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R (2008) Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy. N Engl J Med 358: 252-260.
29. Leucht S, Hierl S, Kissling W, Dold M, Davis JM (2012) Putting the efficacy of psychiatric and general medicine medication into perspective: review of metaanalyses. The British Journal of Psychiatry 200: 97-106. doi:10.1192/bjp.bp.111.096594.
30. DeRubeis RJ, Siegle GJ, Hollon SD (2008) Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms. Nat Rev Neurosci 9: 788-796. doi:10.1038/nrn2345.
31. Uhr M, Tontsch A, Namendorf C, Ripke S, Lucae S, et al. (2008) Polymorphisms in the Drug Transporter Gene ABCB1 Predict Antidepressant Treatment Response in Depression. Neuron 57: 203-209. doi:10.1016/j.neuron.2007. 11.017.
32. McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, et al. (2013) Toward a Neuroimaging Treatment Selection Biomarker for Major Depressive Disorder. JAMA Psychiatry: 1-9. doi:10.1001/jamapsychiatry.2013.143.
33. Ising M, Lucae S, Binder EB, Bettecken T, Uhr M, et al. (2009) A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry 66: 966-975. doi:10.1001/archgenpsychiatry.2009.95.
34. Arranz MJ, Kapur S (2008) Pharmacogenetics in Psychiatry: Are We Ready for Widespread Clinical Use? Schizophrenia Bulletin 34: 1130-1144. doi:10.1093/schbul/sbn114.
35. Perlis RH (2011) Translating biomarkers to clinical practice. Mol Psychiatry 16: 1076-1087. doi:10.1038/mp.2011.63.
36. Uher R (2011) Genes, environment, and individual differences in responding to treatment for depression. Harvard review of psychiatry 19: 109-124. doi:10.3109/10673229.2011.586551.
37. Dunlop BW, Binder EB, Cubells JF, Goodman MG, Kelley ME, et al. (2012) Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT): Study Protocol for a Randomized Controlled Trial. Trials 13. doi:10.1186/1745-6215-13-106.
38. Kraemer HC, Wilson GT, Fairburn CG, Agras WS (2002) Mediators and moderators of treatment effects in randomized clinical trials. Arch Gen Psychiatry 59: 877.
39. Kraemer HC, Frank E, Kupfer DJ (2006) Moderators of treatment outcomes: clinical, research, and policy importance. JAMA 296: 1286-1289. doi:10.1001/jama.296.10.1286. (Pubitemid 44394901)
40. Byar DP, Corle DK (1977) Selecting optimal treatment in clinical trials using covariate information. J Chronic Dis 30: 445-459. (Pubitemid 8154987)
41. Byar DP (1985) Assessing apparent treatment - covariate interactions in randomized clinical trials. Stat Med 4: 255-263. doi:10.1002/sim.4780040304.
42. Yakovlev A, Goot RE, Osipova TT (1994) The choice of cancer treatment based on covariate information. Stat Med 13: 1575-1581. doi:10.1002/sim. 4780131508. (Pubitemid 24273806)